Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse events among patients in the PET-based group compared to the non-PET-based group. Evidence Rating Level: 1 (Excellent) Study Rundown: Human epidermal growth factor receptor 2-positive (HER2-positive) breast cancers are associated with a high risk of